What is the long-term trend for CorMedix's operating loss carryforwards valuation allowance?

Over 2 years (2023 to 2025), CorMedix's operating loss carryforwards valuation allowance has grown at a 84.3% compound annual growth rate (CAGR), from $13.02M to $44.2M.

CorMedix CRMD Operating Loss Carryforwards Valuation Allowance

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:OperatingLossCarryforwardsValuationAllowance.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's operating loss carryforwards valuation allowance.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's operating loss carryforwards valuation allowance?: CorMedix (CRMD) reported operating loss carryforwards valuation allowance of $44.2M in Q4 2025.
What is the long-term trend for CorMedix's operating loss carryforwards valuation allowance?: Over 2 years (2023 to 2025), CorMedix's operating loss carryforwards valuation allowance has grown at a 84.3% compound annual growth rate (CAGR), from $13.02M to $44.2M.